Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.jad.2011.04.032
Title: | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report | Authors: | Bobo, W.V. Chen, H. Trivedi, M.H. Stewart, J.W. Nierenberg, A.A. Fava, M. Kurian, B.T. Warden, D. Morris, D.W. Luther, J.F. Husain, M.M. Cook, I.A. Lesser, I.M. Kornstein, S.G. Wisniewski, S.R. Rush, A.J. Shelton, R.C. |
Keywords: | Bupropion Escitalopram Major depressive disorder Melancholic features Mirtazapine Venlafaxine |
Issue Date: | Oct-2011 | Citation: | Bobo, W.V., Chen, H., Trivedi, M.H., Stewart, J.W., Nierenberg, A.A., Fava, M., Kurian, B.T., Warden, D., Morris, D.W., Luther, J.F., Husain, M.M., Cook, I.A., Lesser, I.M., Kornstein, S.G., Wisniewski, S.R., Rush, A.J., Shelton, R.C. (2011-10). Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. Journal of Affective Disorders 133 (3) : 467-476. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jad.2011.04.032 | Abstract: | Background: The clinical effects of antidepressant combinations vs. monotherapy as initial treatment for major depression with melancholic features (MDD-MF) are unknown. Methods: Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram + placebo (the MONO condition), bupropion-sustained release + escitalopram, or venlafaxine-extended release + mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial. Secondary data analyses were conducted to compare demographic and clinical characteristics, and contrast clinical responses according to drug treatment, in patients with MDD-MF (n = 124) and non-melancholic MDD (n = 481). Results: While numerically lower, remission rates in MDD-MF did not differ significantly from those with non-melancholic MDD either at 12 (33.1% vs. 41.0%, aOR 1.16, p = 0.58) or 28 (39.5% vs. 46.8%, aOR = 1.02, p = 0.93) weeks of treatment. Remission rates did not differ significantly between combination and monotherapy groups in either MDD-MF or non-melancholic MDD patients at either time point. Similar conclusions were reached for response rates, premature study discontinuation, and self-rated depression symptom severity. Limitations: This is a secondary analysis of data from the CO-MED trial, which was not designed to address differential treatment response in melancholic and non-melancholic MDD. Conclusions: We found no evidence of differential remission or response rates to antidepressant combination or monotherapy between melancholic/non-melancholic MDD patients, or according to antidepressant treatment group, after 12 and 28 weeks. Melancholic features may not be a valid predictor of more favorable response to antidepressant combination therapy as initial treatment. © 2011 Elsevier B.V. All rights reserved. | Source Title: | Journal of Affective Disorders | URI: | http://scholarbank.nus.edu.sg/handle/10635/110621 | ISSN: | 01650327 | DOI: | 10.1016/j.jad.2011.04.032 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.